Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07754994

Medication Self-Management Technology for Older Adults

The goal of this feasibility study is to evaluate the preliminary impact of a mobile health application (app) called bpMedManage-R, designed to support hypertension medication self-management in persons with mild cognitive impairment (PwMCI) who live alone. The main questions this study aims to answer are whether the bpMedManage-R app shows preliminary impact on medication-related self-regulation (the ability to consistently take medications as prescribed) and self-efficacy (confidence in independently managing medication use). Participants will be randomized after a baseline assessment to the bpMedManage-R Immediate Group or the bpMedManage-R Delayed Group. Participants assigned to the Immediate Group will complete a 4-week baseline adherence period, at the end of which they will enter the intervention phase. A remote training session will be conducted to initiate the intervention phase, during which participants will download the app, learn to use it, and set up their medication schedule and reminders within the app with support from the study team. They will then use the app for 8 weeks to self-manage their medications, take part in brief weekly check-ins to review progress, and complete Outcome Assessment 1 at the end of the 8-week intervention phase. Participants assigned to the Delayed Group will complete a 12-week baseline adherence period, at the end of which they will complete Outcome Assessment 1. Subsequently, they will enter the intervention phase and will follow a process similar to that of the Immediate Group. At the end of the 8-week intervention phase, they will complete Outcome Assessment 2. Researchers will compare participants who receive the bpMedManage-R app intervention immediately to those assigned to the delayed control group.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 60+
  • Fluent in English
  • Adequate visual and auditory acuity
  • Community dwelling
  • Lives alone
  • Self-reported memory problems
  • Manage at least one hypertension medication
  • Passing score on Telephone Interview for Cognitive Status - Modified (TICS- M) between 27-37
  • Passing score on Montreal Cognitive Assessment (MoCA) between 20 and 26
  • Geriatric Depression Scale (GDS) score of 6 or lower
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

  • Diagnosis of dementia
  • Major communication difficulties

Treatment and study plan

Immediate Intervention Arm

Other

Participants will first complete a 4 week baseline medication adherence monitoring period. After this period, they will attend a video conferencing session with the research team to receive guidance on downloading and using the bpMedManage R app. They will also set personalized goals for self-monitoring their medication daily and weekly using the app. Participants will then use the app for 8 weeks to monitor their medication adherence along with brief weekly check ins to address questions or technical issues. At the end of the 8 week intervention, participants will complete a final assessment.

Delayed Intervention Arm

Other

Participants will first complete a 12 week baseline medication adherence monitoring period. At the end of this period, they will attend a video conferencing session with the research team during which they will complete a brief assessment and receive guidance on downloading and using the bpMedManage R app. They will also set personalized goals for self-monitoring their medication daily and weekly using the app. Participants will then use the app for 8 weeks, along with brief weekly check ins to address questions or technical issues. At the end of the 8 week intervention, they will complete a final assessment.

Primary outcomes

  1. Change in Self-regulation Measured by Adapted Short Self-Regulation Questionnaire (SSRQ)

    Time frame: Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

    A 31-item measure of the ability to regulate behavior in order to achieve desired future outcomes.

  2. Change in Medication Usage Self-efficacy Measured by Medication Usage Self-Efficacy (MUSE) questionnaire

    Time frame: Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

    A brief 8-item tool that measures how confident a person is in understanding and taking their prescribed medications.

  3. Change in Medication Usage Self-efficacy Measured by Medication Adherence Self-Efficacy Scale-revised (MASES-R)

    Time frame: Immediate Group: Baseline; 8 weeks post-intervention Delayed Group: Baseline; 8 weeks post wait-list period; 8 weeks post-intervention

    A13-item questionnaire that measures a person's confidence in taking their medication even when faced with difficult situations.

Study contacts

Contact information is provided by the study sponsor or research team.

Raksha Mudar

CONTACT

[email protected]

217-333-4718

Sponsors and collaborators

Lead sponsor

University of Illinois at Urbana-Champaign

Other

Collaborators

  • Arizona State University

Registry information

Official study title

Remote Hypertension Medication Self-Management Technology for Older Adults

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Aug 10, 2026
Registry last updated
Aug 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.